Preamble to the 2015 SITC immunotherapy biomarkers taskforce

Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, Samir N. Khleif, Francesco M. Marincola

Research output: Contribution to journalComment/debate

3 Citations (Scopus)

Abstract

The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.

Original languageEnglish (US)
Article number8
JournalJournal for ImmunoTherapy of Cancer
Volume3
Issue number1
DOIs
StatePublished - Mar 24 2015

Fingerprint

Tumor Biomarkers
Immunotherapy
Biomarkers
Technology
Immunologic Monitoring
Tumor Microenvironment
Immunity
Neoplasms
Clinical Trials
Education
Therapeutics

Keywords

  • Biomarkers
  • Clinical trial
  • Immune monitoring
  • Immunotherapy
  • Taskforce

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Butterfield, L. H., Disis, M. L., Fox, B. A., Khleif, S. N., & Marincola, F. M. (2015). Preamble to the 2015 SITC immunotherapy biomarkers taskforce. Journal for ImmunoTherapy of Cancer, 3(1), [8]. https://doi.org/10.1186/s40425-015-0052-6

Preamble to the 2015 SITC immunotherapy biomarkers taskforce. / Butterfield, Lisa H.; Disis, Mary L.; Fox, Bernard A.; Khleif, Samir N.; Marincola, Francesco M.

In: Journal for ImmunoTherapy of Cancer, Vol. 3, No. 1, 8, 24.03.2015.

Research output: Contribution to journalComment/debate

Butterfield, LH, Disis, ML, Fox, BA, Khleif, SN & Marincola, FM 2015, 'Preamble to the 2015 SITC immunotherapy biomarkers taskforce', Journal for ImmunoTherapy of Cancer, vol. 3, no. 1, 8. https://doi.org/10.1186/s40425-015-0052-6
Butterfield, Lisa H. ; Disis, Mary L. ; Fox, Bernard A. ; Khleif, Samir N. ; Marincola, Francesco M. / Preamble to the 2015 SITC immunotherapy biomarkers taskforce. In: Journal for ImmunoTherapy of Cancer. 2015 ; Vol. 3, No. 1.
@article{4ee77314259d463294629ce3218e5825,
title = "Preamble to the 2015 SITC immunotherapy biomarkers taskforce",
abstract = "The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.",
keywords = "Biomarkers, Clinical trial, Immune monitoring, Immunotherapy, Taskforce",
author = "Butterfield, {Lisa H.} and Disis, {Mary L.} and Fox, {Bernard A.} and Khleif, {Samir N.} and Marincola, {Francesco M.}",
year = "2015",
month = "3",
day = "24",
doi = "10.1186/s40425-015-0052-6",
language = "English (US)",
volume = "3",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Preamble to the 2015 SITC immunotherapy biomarkers taskforce

AU - Butterfield, Lisa H.

AU - Disis, Mary L.

AU - Fox, Bernard A.

AU - Khleif, Samir N.

AU - Marincola, Francesco M.

PY - 2015/3/24

Y1 - 2015/3/24

N2 - The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.

AB - The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.

KW - Biomarkers

KW - Clinical trial

KW - Immune monitoring

KW - Immunotherapy

KW - Taskforce

UR - http://www.scopus.com/inward/record.url?scp=84977100953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977100953&partnerID=8YFLogxK

U2 - 10.1186/s40425-015-0052-6

DO - 10.1186/s40425-015-0052-6

M3 - Comment/debate

AN - SCOPUS:84977100953

VL - 3

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 8

ER -